WuXi Biologics Financials

Market Capitalization HK$72.27 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	27.56
Forward PE	17.13
Price to Sales TTM	HK$4.22
Price to Book MRQ	HK$1.80
Enterprise to Revenue	4.36
Enterprise to EBITDA	16.40

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	15.38%
Operating Margin	21.22%
Return on Assets TTM	3.98%
Return on Equity TTM	7.20%

Income Statement

Revenue TTM	HK$18,370,064,233
Revenue per Share TTM	HK$4.14
Quarterly Revenue Growth	1.00%
Gross Profit TTM	HK$7,101,876,332
EBITDA	HK$5,705,535,000
Net Income to Common TTM	HK$2,824,916,638
Diluted EPS TTM	HK$0.64
Quarterly Earnings Growth YoY	-33.90%

Balance Sheet

Total Cash MRQ	HK$10,226,582,259
Total Cash per Share MRQ	HK$2.30
Total Debt MRQ	HK$
Total Debt to Equity MRQ	10.23
Current Ratio MRQ	2.91
Book Value per Share MRQ	HK$9.79

Cash Flow

Operating Cash Flow TTM	HK$3,455,565,589
Levered Free Cash Flow TTM	HK$-1,054,695,416

2269 Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	4,096,719,872
Float Shares	3,545,299,494
Avg 10 Volume	44,497,457
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	14.80%
% Held by Institutions	34.72%

Stock Price Summary

Beta	0.61
Fifty Two Week Low	HK$10.14
Fifty Two Week High	HK$25.70
Fifty Two Week Change	-26.92%
Day 50 MA	HK$16.70
Day 200 MA	HK$14.03

Dividends and Splits

Forward Annual Dividend Rate	HK$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	HK$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2020-11-16